FDA approves second weight loss medication this year

General Health
Coverage of the FDA's approval of Vivus' Qsymia (phentermine/topiramate) was extensive with a focus on adding to the options available to physicians and patients for treating obesity. All stories noted previous problems with weight loss medications and the FDA's previous rejection of it, as well as the other weight loss medication approved earlier this year. Stories also mentioned dangers of birth defects and worries about heart attacks. (more…)
Read More